ClinicalTrials.gg
CompletedNCT02303626OPuS-2Updated Nov 17, 2025Results posted

12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks

A Phase 2/3 interventional study of BCX4161 and Placebo in Hereditary Angioedema and HAE, sponsored by BioCryst Pharmaceuticals. Completed at 40 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by BioCryst Pharmaceuticals · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals — 2 open to participants now, 5 under way, 4 of them phase 3. Angioedemas, Hereditary · BioCryst Pharmaceuticals.

Enrollment
7th of 21
110 · median 54
Started
2014
with 2 others
Phase 2/3
2 of 22
none open now
Registered
4th of 22
by date

Among the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, this one is the 7th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2014, is one of 2 in phase 2/3, and was the 4th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

2 of the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of an oral treatment, BCX4161, in preventing acute attacks in participants with hereditary angioedema (HAE). Eligible participants will be randomized to receive one of two doses of BCX4161 or placebo for 12 weeks. The study will compare the number of acute attacks in each treatment group, as well as a number of other clinical outcomes, and the safety and tolerability of each dose of BCX4161 compared to placebo.

03

Conditions studied

  • Hereditary Angioedema
  • HAE

Keywords

  • BCX4161
  • Prophylaxis
  • Prevention
  • HAE
  • Hereditary Angioedema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. A clinical diagnosis of HAE type I or II
  2. Documented HAE attacks within a defined calendar period; in the absence of documented HAE attacks, participants will be required to enter a run-in period to document attacks
  3. Access to acute attack medications
  4. Sexually active women of and sexually active men must utilize highly effective

Key Exclusion Criteria:

  1. Women who are pregnant or breast-feeding
  2. Any clinical condition or medical history that would interfere with the subject's safety or ability to participate in the study
  3. Use of C1INH or tranexamic acid for prophylaxis of HAE attacks
  4. Current participation in any other drug study or within the last 30 days
  5. History of or current alcohol or drug abuse
  6. Infection with , or
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    BCX4161 300 mg three times daily

    Three BCX4161 capsules (100 mg) and two placebo capsules to be taken three times daily by mouth

    Drug: BCX4161 · Drug: Placebo

  • Experimental
    BCX4161 500 mg three times daily

    Five BCX4161 capsules (100 mg) to be taken three times daily by mouth

    Drug: BCX4161

  • Placebo comparator
    Placebo three times daily

    Five placebo capsules to be taken three times daily by mouth

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The Mean Acute Angioedema Attack Rate

    An angioedema attack was defined as swelling at any location reported by participant, which had no swelling earlier. Total number of confirmed attacks during the treatment period standardized to a weekly attack-rate to adjust for the total duration of treatment. The attack rate was derived for each participant by treatment period. The weekly attack rate was equal to the total number of confirmed attacks during a treatment period divided by the duration of the treatment (in days) times 7 days.

    Time frame: 12 weeks

Secondary outcomes

  1. Number of Attack-free Days

    The number of attack free days was the sum of the days during the treatment period for which participants reported no attacks.

    Time frame: 12 weeks

  2. Number of Participants Who Are Attack-free

    The number of participants who reported no attacks during the 12-week treatment period.

    Time frame: 12 weeks

  3. Disease Activity, as Measured by the 84-day Angioedema Activity Score

    Angioedema Activity Score (AAS) consists of 5 questions (period in which swelling occurred, physical discomfort, daily activity restriction, cosmetic disfigurement, and overall severity) to be answered for each day during which a subject experiences an HAE attack. A score between 0 (no symptoms) and 3 (Severe symptoms) was assigned to the responses for each question and the total daily score will be derived as the sum of the 5 question scores for each day during which the subject experiences a confirmed attack. Daily AAS ranged from 0 to 15 with higher scores indicating the greater disease severity. For participants who completed the study, the 84-day AAS was obtained by sum of AAS score during the treatment period and ranged from 0 (best) to 1,260 (worst).For participants who discontinued the study prematurely the 84-day AAS was obtained using the formula: Sum of AAS score of each day on treatment ∗ 84/Number of days on treatment.

    Time frame: 12 weeks

  4. Change From Baseline at Week 12, in Quality of Life as Measured by the Angioedema Quality of Life Questionnaire

    Angioedema Quality of Life questionnaire (AE-QoL) consisted of 4 domains (i.e., functioning, fatigue/mood, fear/shame, and nutrition) and a total score based on a total of 17 possible responses. The results of all the responses are summed up and transformed to a scale ranging from 0 (best) to 100 (worst).

    Time frame: Baseline (Day 1) and Week 12

  5. Number of Participants With Treatment Emergent Adverse Events

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant. No causal relationship with study drug or with the clinical study itself is implied. An AE could be an unfavorable and unintended sign, symptom (including an abnormal laboratory finding), syndrome, or illness that developed or worsened during the clinical study. A serious adverse event (SAE) is any untoward medical occurrence resulting in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or other medically important event. Any graded abnormality that occurred following the initiation of study drug and up to 30 days after the last dose of study drug, and represented at least a 1-grade increase from the baseline assessment, was defined as treatment emergent.

    Time frame: From first dose up to 14 weeks

  6. Change From Baseline at Week 12 in Quality of Life, as Measured by the EuroQoL Five-dimensional, 5-level Questionnaire

    The EuroQoL five-dimensional, 5-level (EQ-5D-5L) was used to assess overall wellbeing and comprised the following five domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain has 5 response levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. It included the EQ Visual Analogue scale (EQ VAS) to rate overall health on a scale of 0 (worst health) to 100 (best health).

    Time frame: Baseline (Day 1) and Week 12

07

Results

Posted Nov 17, 2025

Participant flow

Participants were recruited from study sites in Belgium, Canada, France, Germany, Hungary, Italy, the United Kingdom and the United States, between December 2014 and October 2015

Participant flow — Overall Study
MilestoneBCX4161 300 mg three times dailyBCX4161 500 mg three times dailyPlacebo three times daily
Started363836
Completed353533
Not completed133
Withdrew: Lack of efficacy101
Withdrew: Adverse event020
Withdrew: Protocol violation010
Withdrew: Pregnancy001
Withdrew: Subject non-compliance001

Outcome measures

PrimaryThe Mean Acute Angioedema Attack Rate

An angioedema attack was defined as swelling at any location reported by participant, which had no swelling earlier. Total number of confirmed attacks during the treatment period standardized to a weekly attack-rate to adjust for the total duration of treatment. The attack rate was derived for each participant by treatment period. The weekly attack rate was equal to the total number of confirmed attacks during a treatment period divided by the duration of the treatment (in days) times 7 days.

Time frame:
12 weeks
Reported as:
Least squares mean · Confirmed attacks per week
The Mean Acute Angioedema Attack Rate
Confirmed attacks per weekBCX4161 300 mg three times dailyBCX4161 500 mg three times dailyPlacebo three times daily
The Mean Acute Angioedema Attack Rate0.675 ± 0.0890.589 ± 0.0860.593 ± 0.088
SecondaryNumber of Attack-free Days

The number of attack free days was the sum of the days during the treatment period for which participants reported no attacks.

Time frame:
12 weeks
Reported as:
Mean · Number of attack-free days
Number of Attack-free Days
Number of attack-free daysBCX4161 300 mg three times dailyBCX4161 500 mg three times dailyPlacebo three times daily
Number of Attack-free Days62.8 ± 18.266.0 ± 17.963.6 ± 14.9
SecondaryNumber of Participants Who Are Attack-free

The number of participants who reported no attacks during the 12-week treatment period.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Are Attack-free
ParticipantsBCX4161 300 mg three times dailyBCX4161 500 mg three times dailyPlacebo three times daily
Number of Participants Who Are Attack-free110
SecondaryDisease Activity, as Measured by the 84-day Angioedema Activity Score

Angioedema Activity Score (AAS) consists of 5 questions (period in which swelling occurred, physical discomfort, daily activity restriction, cosmetic disfigurement, and overall severity) to be answered for each day during which a subject experiences an HAE attack. A score between 0 (no symptoms) and 3 (Severe symptoms) was assigned to the responses for each question and the total daily score will be derived as the sum of the 5 question scores for each day during which the subject experiences a confirmed attack. Daily AAS ranged from 0 to 15 with higher scores indicating the greater disease severity. For participants who completed the study, the 84-day AAS was obtained by sum of AAS score during the treatment period and ranged from 0 (best) to 1,260 (worst).For participants who discontinued the study prematurely the 84-day AAS was obtained using the formula: Sum of AAS score of each day on treatment ∗ 84/Number of days on treatment.

Time frame:
12 weeks
Reported as:
Mean · score on a scale
Disease Activity, as Measured by the 84-day Angioedema Activity Score
score on a scaleBCX4161 300 mg three times dailyBCX4161 500 mg three times dailyPlacebo three times daily
Disease Activity, as Measured by the 84-day Angioedema Activity Score113.9 ± 101.988.5 ± 85.197.2 ± 77.3
SecondaryChange From Baseline at Week 12, in Quality of Life as Measured by the Angioedema Quality of Life Questionnaire

Angioedema Quality of Life questionnaire (AE-QoL) consisted of 4 domains (i.e., functioning, fatigue/mood, fear/shame, and nutrition) and a total score based on a total of 17 possible responses. The results of all the responses are summed up and transformed to a scale ranging from 0 (best) to 100 (worst).

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 12, in Quality of Life as Measured by the Angioedema Quality of Life Questionnaire
score on a scaleBCX4161 300 mg three times dailyBCX4161 500 mg three times dailyPlacebo three times daily
Change From Baseline at Week 12, in Quality of Life as Measured by the Angioedema Quality of Life Questionnaire-9.89 ± 3.11-17.45 ± 2.66-12.14 ± 2.64
SecondaryNumber of Participants With Treatment Emergent Adverse Events

An adverse event (AE) is any untoward medical occurrence in a clinical study participant. No causal relationship with study drug or with the clinical study itself is implied. An AE could be an unfavorable and unintended sign, symptom (including an abnormal laboratory finding), syndrome, or illness that developed or worsened during the clinical study. A serious adverse event (SAE) is any untoward medical occurrence resulting in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or other medically important event. Any graded abnormality that occurred following the initiation of study drug and up to 30 days after the last dose of study drug, and represented at least a 1-grade increase from the baseline assessment, was defined as treatment emergent.

Time frame:
From first dose up to 14 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsBCX4161 300 mg three times dailyBCX4161 500 mg three times dailyPlacebo three times daily
Number of Participants With Treatment Emergent Adverse Events313532
SecondaryChange From Baseline at Week 12 in Quality of Life, as Measured by the EuroQoL Five-dimensional, 5-level Questionnaire

The EuroQoL five-dimensional, 5-level (EQ-5D-5L) was used to assess overall wellbeing and comprised the following five domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain has 5 response levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. It included the EQ Visual Analogue scale (EQ VAS) to rate overall health on a scale of 0 (worst health) to 100 (best health).

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 12 in Quality of Life, as Measured by the EuroQoL Five-dimensional, 5-level Questionnaire
score on a scaleBCX4161 300 mg three times dailyBCX4161 500 mg three times dailyPlacebo three times daily
Change From Baseline at Week 12 in Quality of Life, as Measured by the EuroQoL Five-dimensional, 5-level Questionnaire3.26 ± 2.382.41 ± 3.139.92 ± 1.72

Adverse events

Collected over From first dose up to 14 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BCX4161 300 mg three times daily0/36 (0%)2/36 (5.6%)31/36 (86.1%)
BCX4161 500 mg three times daily0/38 (0%)3/38 (7.9%)35/38 (92.1%)
Placebo three times daily0/36 (0%)3/36 (8.3%)32/36 (88.9%)
Most frequent serious events
Most frequent serious events
EventBCX4161 300 mg three times dailyBCX4161 500 mg three times dailyPlacebo three times daily
Hereditary angioedemaCongenital, familial and genetic disorders2/361/381/36
Back painMusculoskeletal and connective tissue disorders0/360/381/36
MigraineNervous system disorders1/360/380/36
Abortion inducedSurgical and medical procedures0/360/381/36
Chest discomfortGeneral disorders0/361/380/36
Chest painGeneral disorders0/361/380/36
Most frequent other events
Showing 10 of 33
Most frequent other events
EventBCX4161 300 mg three times dailyBCX4161 500 mg three times dailyPlacebo three times daily
DiarrhoeaGastrointestinal disorders8/3616/3812/36
FlatulenceGastrointestinal disorders5/3610/389/36
NasopharyngitisInfections and infestations5/368/387/36
HeadacheNervous system disorders4/367/386/36
NauseaGastrointestinal disorders4/363/383/36
Abdominal painGastrointestinal disorders3/364/382/36
Abdominal distensionGastrointestinal disorders3/362/382/36
Faeces softGastrointestinal disorders1/361/383/36
SinusitisInfections and infestations1/361/383/36
Blood alkaline phosphatase increasedInvestigations3/360/380/36

Baseline characteristics

Age, Continuous
Age, Continuous(years)BCX4161 300 mg Three Times DailyBCX4161 500 mg Three Times DailyPlacebo Three Times DailyTotal
Mean40.4 ± 12.441.1 ± 15.142.1 ± 12.541.2 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)BCX4161 300 mg Three Times DailyBCX4161 500 mg Three Times DailyPlacebo Three Times DailyTotal
Female29302685
Male781025
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BCX4161 300 mg Three Times DailyBCX4161 500 mg Three Times DailyPlacebo Three Times DailyTotal
American Indian or Alaska Native1001
Asian1102
Native Hawaiian or Other Pacific Islander1012
Black or African American0000
White323634102
More than one race0000
Unknown or Not Reported1113
Region of Enrollment
Region of Enrollment(Participants)BCX4161 300 mg Three Times DailyBCX4161 500 mg Three Times DailyPlacebo Three Times DailyTotal
Canada3115
Hungary1146
Belgium0112
United States19191755
Italy1405
United Kingdom65314
France3126
Germany36817
Qualifying attack rate
Qualifying attack rate(Attacks/ week)BCX4161 300 mg Three Times DailyBCX4161 500 mg Three Times DailyPlacebo Three Times DailyTotal
Mean0.93 ± 0.390.95 ± 0.390.92 ± 0.340.93 ± 0.37
08

Study locations

40 sites
  • Birmingham, Alabama 35209, United States
  • Scottsdale, Arizona 85251, United States
  • Granada Hills, California 91344, United States
  • San Diego, California 92093, United States
  • San Diego, California 92112, United States
  • Walnut Creek, California 94598, United States
  • Colorado Springs, Colorado 80907, United States
  • Shreveport, Louisiana 71106, United States
  • Chevy Chase, Maryland 20815, United States
  • Boston, Massachusetts 02114, United States
  • Plymouth, Minnesota 55446, United States
  • St Louis, Missouri 63141, United States
  • New York, New York 10029, United States
  • Charlotte, North Carolina 28277, United States
  • Cincinnati, Ohio 45267, United States
  • Oklahoma City, Oklahoma 73131, United States
  • Tulsa, Oklahoma 74133, United States
  • Lake Oswego, Oregon 97035, United States
  • Hershey, Pennsylvania 17033, United States
  • Pittsburgh, Pennsylvania 15241, United States
  • Dallas, Texas 75231, United States
  • Galveston, Texas 77555, United States
  • Fairfax, Virginia 63141, United States
  • Spokane, Washington 99204, United States
  • Tacoma, Washington 98405, United States
  • Leuven, Belgium
  • Ottawa, Canada
  • Grenoble, France
  • Lille, France
  • Paris, France
  • Berlin, Germany
  • Frankfurt, Germany
  • Mörfelden-Walldorf, Germany
  • Budapest, Hungary
  • Milan, Italy
  • Birmingham, United Kingdom
  • Bristol, United Kingdom
  • Cardiff, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
09

References and documents

Publications

  • Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2. PubMed 36326435 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2014 to primary completion in Jan 2016, 13 months.

Results were first posted in Nov 2025, 9 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2014
First posted
Dec 1, 2014
StartActual
Dec 17, 2014
Primary completionActual
Jan 2016
CompletionActual
Jan 2016
Results first posted
Nov 17, 2025
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02303626
Responsible party
Sponsor
First posted
Dec 1, 2014
Start date
Dec 17, 2014
Primary completion
Jan 2016
Completion
Jan 2016
Results posted
Nov 17, 2025
Last update
Nov 17, 2025

Study contacts

Marc Riedl, MD MS
principal investigator · UCSD

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avoralstat

Start the discussion